1[1]Crawford R. Gynecologic oncology:current diagnosis and treatment. London: WB Saunders, 1996. 203～212.
2[2]Santin AD, Ioli GR, Hiserodt JC, et al. Development and characterization of an IL - 4 - secreting human ovarian carcinoma cell line. Gynecol Oncol, 1995,58: 230.
3[3]Santin AD, Ioli GR, Hiserodt JC, et al. Development and characterization of an interleukin - 2 - transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. Am J Obstet Gynecol, 1996,174 (2), 633.
4[4]D' Incan C, Sanches R, Kuiper M, et al. Gamma - interferon gene transfer as a therapeutic strategy for ovarian cancer. Adv Exp Med Biol, 1998,451: 349.
5[5]Nakamura Y, Wakimoto H, Abe J, et al. Adoptive immunotherapy with murine tumor- specific T lymphocytes engineered to secret interleukin 2. Cancer Res, 1994,54: 5757.
6[6]Itoh Y, Koshita Y, Takahashi M, et al. Characterizaton of tumor-necrosis - factor - gene - transduced tumor - infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate,adhesion molecule expression and cytokine production. Cancer Immuno Immunother, 1995,40: 95.
7[7]Sanches R, Kuiper M, Penault - Llorca F, et al. Antitumor effect of interleukin - 12- secreting fibroblasts in a mouse model of ovarian cancer: implication for the use of ovarian cancer biopsy - derived fibriblasts as a vehicle for regional gene therapy. Cancer Gene Ther,2000,7(5) :707.
8[8]Waston JM, Berek JS, Maza OM. Growth inhibition of ovarian cells induced by antisense IL- 6 oligonucleotides. Gynecol Oncol,1993,49: 8.
9[9]Wu S, Meeker AM, Wiener JR, et al. Transfection of ovarian cancer cells with tumor necrosis factor- α (TNF- α ) antisense mRNA abolishes the proliferative response to interleukin- 1 (IL- 1 )but not TNF - . Gynecol Oncol, 1994,53: 59.
10[12]Dorigo O, Shawler DL, Royston I, et al. Combination of transforming growth factor antisense and interleukin - 2 gene therapy in the murine ovarian teratoma model. Gynecol Oncol, 1998,71: 204.
同被引文献42
1Cemazar M, Sersa G, Wilson J, et al. Effective gene transfer to solid tumors using different nonviral gene delivery techniques:electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther, 2002, 9(4):399
2Al-Hendy A, Magliocco A M, Al-Tweigeri T, et al. Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol, 2000 Mar,182(3):
3Burke F, East N, Upton C, et al. interfer on gamma induces cell cycle arrest and apoptosis in a mode if ovarian cancer: enhance ment of effect by batimastat. Eur-J-Cancer, 1997,33(7):1114
4Kigawa J, Terakawa N. Adenovirus-mediated transfer of a p53gene in ovarian cancer. Adv Exp Med Biol. 2000,465:207
5Song K, Cowan K H, Sinha B K. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncol Res. 1999,11(3):153
6Arap W,Nishikawa R,Furnari F B, et al. Replacement of the P16/CDKN2 gene suppresses human glioma cell growth. Cancer Res,1995,55(6):1351
7Minaguchi T, Mori T, Kanamori Y, et al. Growth suppression of human ovarian cancer cells by adenovirus mediated transfer of the PTEN gene. Cancer Res,1999,59(24):6063
8Waston J M,Berek J S, Maza O M. Growth inhibition of ovarian cells induced by antisense IL-6 oligonucleotides . Gynecol Oncol,1993,49:8
9Kramm C M, Niehues T, Rainov N G. Experimental strategies for combined suicide and immune cancer gene therapy. An overview.Methods Mol Biol, 2003,215:137
10Russell W C. Update on adenovirus and its vectors. J Gen Virol 2000,81:2573
